Ionis Pharmaceuticals (IONS) Revenue (2009 - 2026)

Ionis Pharmaceuticals' Revenue history runs 18 years deep, the most recent figure standing at $246.1 million for Q1 2026.

• In Q1 2026, Revenue rose 86.98% year-over-year to $246.1 million; the TTM figure through Mar 2026 stood at $608.1 million (down 15.21% YoY), while the FY2025 annual figure was $943.7 million, up 33.83% from the prior year.
• Revenue was $246.1 million for Q1 2026 at Ionis Pharmaceuticals, up from $203.3 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $324.5 million in Q4 2023 to a low of $2.0 million in Q2 2025.
• Historically, Revenue has averaged $165.9 million across 5 years, with a median of $151.9 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Revenue soared 113.64% in 2023, then slumped 99.11% in 2025.
• A 5-year view of Revenue shows it stood at $151.9 million in 2022, then soared by 113.64% to $324.5 million in 2023, then slumped by 30.18% to $226.6 million in 2024, then declined by 10.26% to $203.3 million in 2025, then advanced by 21.03% to $246.1 million in 2026.
• The last three Revenue figures came in at $246.1 million (Q1 2026), $203.3 million (Q4 2025), and $156.7 million (Q3 2025), per Business Quant data.